Search results
Showing 196 to 210 of 1505 results for patients and public
In development Reference number: GID-TA11203 Expected publication date: 08 April 2026
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
In development Reference number: GID-TA11468 Expected publication date: 14 May 2026
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
In development Reference number: GID-HST10063 Expected publication date: TBC
This document contains advice to help you access treatments and care that NICE has recommended
This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.
This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.
View quality statements for QS121Show all sections
Sections for QS121
- Quality statements
- Quality statement 1: Advice on self-limiting conditions
- Quality statement 2: Back-up (delayed) prescribing
- Quality statement 3: Recording information
- Quality statement 4: Microbiological samples
- Quality statement 5: Data collection and feedback
- Quality statement 6 (developmental statement): electronic prescribing systems
- Update information
Total hip arthroplasty using the superpath approach for osteoarthritis
In development Reference number: GID-IPG10204 Expected publication date: TBC
In development Reference number: GID-HST10054 Expected publication date: 20 February 2026
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.